Product Pathways
BCP0001 GDC-0941
GDC-0941 is a potent inhibitor of PI3Kα, PI3Kβ, PI3Kδ and PI3Kγ ;10G in stock
BCP0002 GDC0449(Vismodegib)
GDC-0449 is a more potent and specific synthetic oral SMO inhibitor,20G in stock
BCP0004 Gefitinib
Gefitinib was found to be a potent inhibitor of EGFR kinase.
BCP0005 Gemcitabine Hydrochloride
A new pyrimidine antimetabolite which has shown good clinical activ.A nucleoside analog of deoxycytidine used in chemotherapy to treat various types of cancer.
BCP0006 GSK1904529A
GSK1904529A is a selective inhibitor of IGF-IR and IR with IC50 of 27 nM and 25 nM, respectively.
BCP0007 GSK461364
GSK461364 is an ATP-competitive inhibitor of Plk1 and forms a rapidly reversible complex with Plk1.
BCP0008 GSK690693
aminofurazan-derived inhibitor of Akt kinases with potential antine
BCP0009 Abiraterone(CB-7598)
A steroidal cytochrome P450 17alpha-hydroxylase-17,20-lyase inhibitor
BCP0010 ABT-263(Navitoclax)
ABT-263 (Navitoclax) is a potent orally bioavailable SMI that is structurally related to ABT-737. ABT-263 disrupts Bcl-2 - Bcl-XL interactions with pro-apoptotic proteins .
BCP0011 ABT737
ABT737,a selective inhibitor of BCL-2, in small cell lung cancer.
第一页 1 2 3 4 5 6 7 8 9 10 下10页 最后页 
Only for research purpose , not for human consumption Copyright©2012 ShangHai Biochempartner Co.,Ltd.